NasdaqGS - Nasdaq Real Time Price USD

Anavex Life Sciences Corp. (AVXL)

3.7400 +0.0600 (+1.63%)
As of 3:08 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Operating Expense
51,665.0000
55,731.0000
50,986.0000
41,948.0000
30,938.3440
Operating Income
-51,665.0000
-55,731.0000
-50,986.0000
-41,948.0000
-30,938.3440
Net Non Operating Interest Income Expense
6,295.0000
5,555.0000
947.0000
26.0000
179.9730
Other Income Expense
2,327.0000
2,678.0000
2,419.0000
4,281.0000
4,500.5650
Pretax Income
-43,043.0000
-47,498.0000
-47,620.0000
-37,641.0000
-26,257.8060
Tax Provision
112.0000
7.0000
358.0000
268.0000
22.6640
Net Income Common Stockholders
-43,155.0000
-47,505.0000
-47,978.0000
-37,909.0000
-26,280.4700
Diluted NI Available to Com Stockholders
-43,155.0000
-47,505.0000
-47,978.0000
-37,909.0000
-26,280.4700
Basic EPS
-0.54
-0.60
-0.62
-0.54
-0.45
Diluted EPS
-0.54
-0.60
-0.62
-0.54
-0.45
Basic Average Shares
80,812.7720
79,787.5960
76,909.9930
69,802.9600
58,194.8940
Diluted Average Shares
80,812.7720
79,787.5960
76,909.9930
69,802.9600
58,194.8940
Total Operating Income as Reported
--
-55,756.0000
-50,986.0000
-42,002.0000
--
Total Expenses
51,665.0000
55,731.0000
50,986.0000
41,948.0000
30,938.3440
Net Income from Continuing & Discontinued Operation
-43,155.0000
-47,505.0000
-47,978.0000
-37,909.0000
-26,280.4700
Normalized Income
-42,957.5000
-47,473.4000
-47,263.8400
-37,714.8200
-26,372.1142
Interest Income
7,259.0000
6,519.0000
947.0000
26.0000
179.9730
Interest Expense
--
964.0000
--
--
--
Net Interest Income
6,295.0000
5,555.0000
947.0000
26.0000
179.9730
EBIT
-42,468.0000
-46,534.0000
-47,620.0000
-37,641.0000
-30,938.3440
EBITDA
-42,468.0000
-46,534.0000
-47,620.0000
-37,641.0000
-30,938.3440
Net Income from Continuing Operation Net Minority Interest
-43,155.0000
-47,505.0000
-47,978.0000
-37,909.0000
-26,280.4700
Total Unusual Items Excluding Goodwill
-250.0000
-40.0000
-904.0000
-266.0000
125.5400
Total Unusual Items
-250.0000
-40.0000
-904.0000
-266.0000
125.5400
Normalized EBITDA
-42,218.0000
-46,494.0000
-46,716.0000
-37,375.0000
-31,063.8840
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
-52.5000
-8.4000
-189.8400
-71.8200
33.8958
9/30/2020 - 8/2/2006

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ANVS Annovis Bio, Inc.
11.77
+2.40%
 
SAVA Cassava Sciences, Inc.
20.58
+0.40%
 
SAVAW Cassava Sciences, Inc.
0.3501
-28.55%
 
AXSM Axsome Therapeutics, Inc.
72.95
+2.59%
 
INMB INmune Bio, Inc.
10.08
-5.13%
 
ALT Altimmune, Inc.
7.71
+3.21%
 
TGTX TG Therapeutics, Inc.
14.49
+2.76%
 
AGEN Agenus Inc.
6.97
+20.71%
 
SLS SELLAS Life Sciences Group, Inc.
1.6800
+9.09%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0500
-1.29%